Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 427 articles:
HTML format
Text format



Single Articles


    July 2017
  1. KHATIB G, Guzel AB, Gulec UK, Vardar MA, et al
    A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Cukurova technique).
    Gynecol Oncol. 2017 Jul 15. pii: S0090-8258(17)31172.
    PubMed     Text format     Abstract available


  2. FALCONE F, Scambia G, Benedetti Panici P, Signorelli M, et al
    Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31025.
    PubMed     Text format     Abstract available


  3. PALEARI L, Gandini S, Provinciali N, Puntoni M, et al
    Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)30977.
    PubMed     Text format     Abstract available


  4. KRISTELEIT R, Davidenko I, Shirinkin V, El-Khouly F, et al
    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31022.
    PubMed     Text format     Abstract available


  5. YUAN X, Zhang J, Li D, Mao Y, et al
    Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2017 Jul 8. pii: S0090-8258(17)31024.
    PubMed     Text format     Abstract available


  6. GREENWADE MM, Moore KN, Gillen JM, Ding K, et al
    Factors influencing clinical trial enrollment among ovarian cancer patients.
    Gynecol Oncol. 2017 Jul 6. pii: S0090-8258(17)30976.
    PubMed     Text format     Abstract available


  7. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30974.
    PubMed     Text format    


  8. SON JH, Chang SJ, Ryu HS
    Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30978.
    PubMed     Text format     Abstract available


  9. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413].
    Gynecol Oncol. 2017 Jul 5. pii: S0090-8258(17)30973.
    PubMed     Text format    


    June 2017
  10. SUN Z, Gilbert L, Ciampi A, Basso O, et al
    Recruitment challenges in clinical research: Survey of potential participants in a diagnostic study of ovarian cancer.
    Gynecol Oncol. 2017 Jun 27. pii: S0090-8258(17)30962.
    PubMed     Text format     Abstract available


  11. VAN DE VRIE R, van Meurs HS, Rutten MJ, Naaktgeboren CA, et al
    Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
    Gynecol Oncol. 2017 Jun 20. pii: S0090-8258(17)30960.
    PubMed     Text format     Abstract available


  12. SZENDER JB, Emmons T, Belliotti S, Dickson D, et al
    Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
    Gynecol Oncol. 2017 Jun 14. pii: S0090-8258(17)30937.
    PubMed     Text format     Abstract available


  13. BEDNAR EM, Oakley HD, Sun CC, Burke CC, et al
    A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30893.
    PubMed     Text format     Abstract available


  14. GRIMM C, Harter P, Alesina PF, Prader S, et al
    The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30936.
    PubMed     Text format     Abstract available


  15. FREY MK, Ellis AE, Koontz LM, Shyne S, et al
    Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
    Gynecol Oncol. 2017 Jun 8. pii: S0090-8258(17)30885.
    PubMed     Text format     Abstract available



  16. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jun 7. pii: S0090-8258(17)30895.
    PubMed     Text format     Abstract available


  17. VOGEL TJ, Goodman MT, Li AJ, Jeon CY, et al
    Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Jun 5. pii: S0090-8258(17)30848.
    PubMed     Text format     Abstract available


  18. SINNO AK, Li X, Thompson RE, Tanner EJ 3rd, et al
    Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.
    Gynecol Oncol. 2017;145:493-499.
    PubMed     Text format     Abstract available


  19. BRACHOVA P, Alvarez NS, Van Voorhis BJ, Christenson LK, et al
    Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid.
    Gynecol Oncol. 2017;145:577-583.
    PubMed     Text format     Abstract available


    May 2017
  20. DILLEY SE, Havrilesky LJ, Bakkum-Gamez J, Cohn DE, et al
    Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.
    Gynecol Oncol. 2017 May 31. pii: S0090-8258(17)30890.
    PubMed     Text format     Abstract available


  21. JAMIESON A, Sykes P, Eva L, Bergzoll C, et al
    Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Gynecol Oncol. 2017 May 23. pii: S0090-8258(17)30879.
    PubMed     Text format     Abstract available


  22. MERT I, Chhina J, Allo G, Dai J, et al
    Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 22. pii: S0090-8258(17)30871.
    PubMed     Text format     Abstract available


  23. DINKIC C, Eichbaum M, Schmidt M, Grischke EM, et al
    Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Gynecol Oncol. 2017 May 18. pii: S0090-8258(17)30852.
    PubMed     Text format     Abstract available


  24. LUTGENDORF SK, Shinn E, Carter J, Leighton S, et al
    Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.
    Gynecol Oncol. 2017 May 17. pii: S0090-8258(17)30846.
    PubMed     Text format     Abstract available


  25. BARBER EL, Doll KM, Gehrig PA
    Hospital readmission after ovarian cancer surgery: Are we measuring surgical quality?
    Gynecol Oncol. 2017 May 15. pii: S0090-8258(17)30851.
    PubMed     Text format     Abstract available


  26. COHEN JG, Prendergast E, Geddings JE, Walts AE, et al
    Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
    Gynecol Oncol. 2017 May 10. pii: S0090-8258(17)30802.
    PubMed     Text format     Abstract available


  27. GARCIA C, Yao A, Camacho F, Balkrishnan R, et al
    A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30847.
    PubMed     Text format     Abstract available


  28. TANENBAUM LM, Mantzavinou A, Subramanyam KS, Del Carmen MG, et al
    Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30795.
    PubMed     Text format     Abstract available


  29. ENG KH, Morrell K, Starbuck K, Spring-Robinson C, et al
    Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30844.
    PubMed     Text format     Abstract available


  30. DE DONATO M, Petrillo M, Martinelli E, Filippetti F, et al
    Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30806.
    PubMed     Text format     Abstract available


  31. GRABOSCH S, Tseng G, Edwards RP, Lankes HA, et al
    Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2017 May 5. pii: S0090-8258(17)30787.
    PubMed     Text format     Abstract available


  32. MENDERES G, Bonazzoli E, Bellone S, Black J, et al
    SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Gynecol Oncol. 2017 May 1. pii: S0090-8258(17)30804.
    PubMed     Text format     Abstract available


    April 2017
  33. COLON-OTERO G, Weroha SJ, Foster NR, Haluska P, et al
    Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
    Gynecol Oncol. 2017 Apr 28. pii: S0090-8258(17)30801.
    PubMed     Text format     Abstract available


  34. VENERIS JT, Darcy KM, Mhawech-Fauceglia P, Tian C, et al
    High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30793.
    PubMed     Text format     Abstract available


  35. BOOKMAN MA, Tyczynski JE, Espirito JL, Wilson TW, et al
    Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30792.
    PubMed     Text format     Abstract available


  36. PETERS ML, Garber JE, Tung N
    Managing hereditary breast cancer risk in women with and without ovarian cancer.
    Gynecol Oncol. 2017 Apr 25. pii: S0090-8258(17)30794.
    PubMed     Text format     Abstract available


  37. KATCHMAN BA, Chowell D, Wallstrom G, Vitonis AF, et al
    Autoantibody biomarkers for the detection of serous ovarian cancer.
    Gynecol Oncol. 2017 Apr 17. pii: S0090-8258(17)30775.
    PubMed     Text format     Abstract available


  38. PHILLIPS A, Balega J, Nevin J, Singh K, et al
    Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
    Gynecol Oncol. 2017 Apr 12. pii: S0090-8258(17)30786.
    PubMed     Text format     Abstract available


  39. SHINN EH, Valentine A, Baum G, Carmack C, et al
    Comparison of four brief depression screening instruments in ovarian cancer patients: Diagnostic accuracy using traditional versus alternative cutpoints.
    Gynecol Oncol. 2017 Apr 8. pii: S0090-8258(17)30240.
    PubMed     Text format     Abstract available


  40. SIDDIQUI MK, Tyczynski J, Pahwa A, Fernandes AW, et al
    Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 7. pii: S0090-8258(17)30770.
    PubMed     Text format     Abstract available


  41. SZENDER JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, et al
    NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30726.
    PubMed     Text format     Abstract available


  42. GARCIA-SOTO AE, Schreiber T, Strbo N, Ganjei-Azar P, et al
    Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30765.
    PubMed     Text format    


  43. CREASMAN WT, Ali S, Mutch DG, Zaino RJ, et al
    Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30233.
    PubMed     Text format     Abstract available


  44. SONG T, Kim MK, Jung YW, Yun BS, et al
    Minimally invasive compared with open surgery in patients with borderline ovarian tumors.
    Gynecol Oncol. 2017 Apr 2. pii: S0090-8258(17)30235.
    PubMed     Text format     Abstract available


  45. HERZOG TJ, Cohn DE
    Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?
    Gynecol Oncol. 2017;145:1-2.
    PubMed     Text format    


    March 2017
  46. WARREN JL, Harlan LC, Trimble EL, Stevens J, et al
    Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30232.
    PubMed     Text format     Abstract available


  47. PARK JY, Kim DY, Suh DS, Kim JH, et al
    Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30239.
    PubMed     Text format     Abstract available


  48. BARBER EL, Dusetzina SB, Stitzenberg KB, Rossi EC, et al
    Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
    Gynecol Oncol. 2017 Mar 30. pii: S0090-8258(17)30230.
    PubMed     Text format     Abstract available


  49. SCOTT SA, van der Zanden C, Cai E, McGahan CE, et al
    Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer.
    Gynecol Oncol. 2017 Mar 27. pii: S0090-8258(17)30228.
    PubMed     Text format     Abstract available


  50. BREGAR A, Deshpande A, Grange C, Zi T, et al
    Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Gynecol Oncol. 2017 Mar 24. pii: S0090-8258(17)30207.
    PubMed     Text format     Abstract available


  51. JANDIAL DA, Brady WE, Howell SB, Lankes HA, et al
    A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 21. pii: S0090-8258(17)30229.
    PubMed     Text format     Abstract available


  52. K AU K, Peterson N, Truesdell P, Reid-Schachter G, et al
    CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Mar 16. pii: S0090-8258(17)30208.
    PubMed     Text format     Abstract available


  53. MCGEE J, Giannakeas V, Karlan B, Lubinski J, et al
    Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30153.
    PubMed     Text format     Abstract available


  54. JESKE YW, Ali S, Byron SA, Gao F, et al
    FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30152.
    PubMed     Text format     Abstract available


  55. NASIOUDIS D, Kanninen TT, Holcomb K, Sisti G, et al
    Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors.
    Gynecol Oncol. 2017 Mar 11. pii: S0090-8258(17)30205.
    PubMed     Text format     Abstract available


  56. WYSHAM WZ, Schaffer EM, Coles T, Roque DR, et al
    Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Gynecol Oncol. 2017 Mar 10. pii: S0090-8258(17)30160.
    PubMed     Text format     Abstract available


  57. COWAN RA, Eriksson AG, Jaber SM, Zhou Q, et al
    A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2017 Mar 9. pii: S0090-8258(17)30121.
    PubMed     Text format     Abstract available


  58. DE ROOIJ BH, Ezendam NP, Nicolaije KA, Caroline Vos M, et al
    Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial.
    Gynecol Oncol. 2017 Mar 7. pii: S0090-8258(17)30162.
    PubMed     Text format     Abstract available


  59. VAN BROEKHOVEN ME, de Rooij BH, Pijnenborg JM, Vos MC, et al
    Illness perceptions and changes in lifestyle following a gynecological cancer diagnosis: A longitudinal analysis.
    Gynecol Oncol. 2017 Mar 6. pii: S0090-8258(17)30157.
    PubMed     Text format     Abstract available


  60. LEE M, Kim EJ, Cho Y, Kim S, et al
    Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Mar 5. pii: S0090-8258(17)30163.
    PubMed     Text format     Abstract available


    February 2017
  61. FOX E, McCuaig J, Demsky R, Shuman C, et al
    Corrigendum to "The sooner the better: Genetic testing following ovarian cancer diagnosis" [Gynecol. Oncol. 137 (2015) 423-429].
    Gynecol Oncol. 2017 Feb 27. pii: S0090-8258(17)30142.
    PubMed     Text format    


  62. CHASE DM, Chaplin DJ, Monk BJ
    The development and use of vascular targeted therapy in ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30075.
    PubMed     Text format     Abstract available


  63. SAED GM, Diamond MP, Fletcher NM
    Updates of the role of oxidative stress in the pathogenesis of ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30154.
    PubMed     Text format     Abstract available


  64. KOMIYAMA S, Manrai M, Takahashi R, Takeya C, et al
    Safe dissection of high paraaortic lymph nodes superior to the renal vein in ovarian, primary peritoneal, or fallopian tube cancer by the "Komiyama's maneuver", a modification of Kocher's maneuver.
    Gynecol Oncol. 2017 Feb 22. pii: S0090-8258(17)30126.
    PubMed     Text format     Abstract available


  65. FELICES M, Chu S, Kodal B, Bendzick L, et al
    IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Gynecol Oncol. 2017 Feb 21. pii: S0090-8258(17)30149.
    PubMed     Text format     Abstract available


  66. BUTTARELLI M, Mascilini F, Zannoni GF, Ciucci A, et al
    Hormone receptor expression profile of low-grade serous ovarian cancers.
    Gynecol Oncol. 2017 Feb 20. pii: S0090-8258(17)30150.
    PubMed     Text format     Abstract available


  67. SIOULAS VD, Schiavone MB, Kadouri D, Zivanovic O, et al
    Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Gynecol Oncol. 2017 Feb 18. pii: S0090-8258(17)30144.
    PubMed     Text format     Abstract available


  68. ROSS J, Braswell KV, da Silva LM, Mujica F, et al
    Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30146.
    PubMed     Text format     Abstract available


  69. MATSUO K, Machida H, Takiuchi T, Garcia-Sayre J, et al
    Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy.
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30115.
    PubMed     Text format     Abstract available


  70. BURGHAUS S, Fasching PA, Haberle L, Rubner M, et al
    Genetic risk factors for ovarian cancer and their role for endometriosis risk.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30143.
    PubMed     Text format     Abstract available


  71. KOHLER RS, Kettelhack H, Knipprath-Meszaros AM, Fedier A, et al
    MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30128.
    PubMed     Text format     Abstract available


  72. SUIDAN RS, Ramirez PT, Sarasohn DM, Teitcher JB, et al
    A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2017 Feb 13. pii: S0090-8258(17)30132.
    PubMed     Text format     Abstract available


  73. SKALLEBERG J, Solheim O, Fossa SD, Smastuen MC, et al
    Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Gynecol Oncol. 2017 Feb 12. pii: S0090-8258(17)30117.
    PubMed     Text format     Abstract available


  74. CARVAJAL-HAUSDORF DE, Schalper KA, Bai Y, Black J, et al
    Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
    Gynecol Oncol. 2017 Feb 11. pii: S0090-8258(17)30079.
    PubMed     Text format     Abstract available


  75. SEAGLE BL, Shahabi S
    Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30125.
    PubMed     Text format     Abstract available


  76. MAI PL, Piedmonte M, Han PK, Moser RP, et al
    Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30119.
    PubMed     Text format     Abstract available


  77. LEFRINGHOUSE JR, Elder JW, Baldwin LA, Miller RW, et al
    Prospective validation of an intraoperative algorithm to guide surgical staging in early endometrial cancer.
    Gynecol Oncol. 2017 Feb 9. pii: S0090-8258(17)30076.
    PubMed     Text format     Abstract available


  78. KENTWELL M, Dow E, Antill Y, Wrede CD, et al
    Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Gynecol Oncol. 2017 Feb 3. pii: S0090-8258(17)30074.
    PubMed     Text format     Abstract available


  79. SMITH JA, Mathew L, Burney M, Nyshadham P, et al
    Corrigendum to 'Equivalency challenge: evaluation of Lipodox(R) as the generic equivalent for Doxil(R) in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363].
    Gynecol Oncol. 2017;144:448.
    PubMed     Text format    


  80. WESTIN SN, Coleman RL
    Individualized Medicine in Ovarian Cancer: Are We There Yet?
    Gynecol Oncol. 2017;144:229-231.
    PubMed     Text format    


  81. COHN DE, Backes FJ, Wallbillich JJ, Bixel K, et al
    Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30067.
    PubMed     Text format     Abstract available


  82. EOH KJ, Park JS, Park HS, Lee ST, et al
    BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30070.
    PubMed     Text format     Abstract available


  83. BREGAR AJ, Alejandro Rauh-Hain J, Spencer R, Clemmer JT, et al
    Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30068.
    PubMed     Text format     Abstract available


  84. DANIELE G, Lorusso D, Scambia G, Cecere SC, et al
    Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
    Gynecol Oncol. 2017;144:256-259.
    PubMed     Text format     Abstract available


    January 2017
  85. WALLACE S, Kumar A, Mc Gree M, Weaver A, et al
    Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
    Gynecol Oncol. 2017 Jan 31. pii: S0090-8258(17)30073.
    PubMed     Text format     Abstract available


  86. CHANAKIRA A, Westmark PR, Ong IM, Sheehan JP, et al
    Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
    Gynecol Oncol. 2017 Jan 29. pii: S0090-8258(17)30066.
    PubMed     Text format     Abstract available


  87. DALTON HJ, Fleming ND, Sun CC, Bhosale P, et al
    Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
    Gynecol Oncol. 2017 Jan 27. pii: S0090-8258(17)30071.
    PubMed     Text format     Abstract available


  88. MATSUO K, Machida H, Takiuchi T, Grubbs BH, et al
    Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.
    Gynecol Oncol. 2017 Jan 26. pii: S0090-8258(17)30063.
    PubMed     Text format     Abstract available


  89. ALETTI GD, Garbi A, Messori P, Achilarre MT, et al
    Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit.
    Gynecol Oncol. 2017 Jan 20. pii: S0090-8258(17)30061.
    PubMed     Text format     Abstract available


  90. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
    Gynecol Oncol. 2017 Jan 19. pii: S0090-8258(17)30059.
    PubMed     Text format     Abstract available


  91. REISS KA, Herman JM, Armstrong D, Zahurak M, et al
    A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian
    Gynecol Oncol. 2017 Jan 18. pii: S0090-8258(17)30060.
    PubMed     Text format     Abstract available


  92. RASMUSSEN EL, Hannibal CG, Dehlendorff C, Baandrup L, et al
    Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
    Gynecol Oncol. 2017 Jan 17. pii: S0090-8258(17)30039.
    PubMed     Text format     Abstract available


  93. HALTIA UM, Andersson N, Yadav B, Farkkila A, et al
    Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
    Gynecol Oncol. 2017 Jan 16. pii: S0090-8258(16)31681.
    PubMed     Text format     Abstract available


  94. LIAO JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, et al
    Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30046.
    PubMed     Text format     Abstract available


  95. VON GRUENIGEN VE, Huang HQ, Beumer JH, Lankes HA, et al
    Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(16)31602.
    PubMed     Text format     Abstract available


  96. GILLEN J, Gunderson C, Greenwade M, Rowland M, et al
    Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
    Gynecol Oncol. 2017 Jan 10. pii: S0090-8258(16)31687.
    PubMed     Text format     Abstract available


  97. ISLAM MM, Banerjee T, Packard CZ, Kotian S, et al
    HDAC10 as a potential therapeutic target in ovarian cancer.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(17)30047.
    PubMed     Text format     Abstract available


  98. TOZZI R, Hardern K, Gubbala K, Garruto Campanile R, et al
    En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(16)31683.
    PubMed     Text format     Abstract available


  99. TUOMI T, Pasanen A, Leminen A, Butzow R, et al
    Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort.
    Gynecol Oncol. 2017 Jan 6. pii: S0090-8258(17)30041.
    PubMed     Text format     Abstract available


  100. RYAN NA, Evans DG, Green K, Crosbie EJ, et al
    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(17)30042.
    PubMed     Text format     Abstract available


  101. GOTTLIEB CE, Mills AM, Cross JV, Ring KL, et al
    Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(16)31685.
    PubMed     Text format     Abstract available


  102. DIZON DS
    Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection.
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31684.
    PubMed     Text format    


  103. SPREAFICO A, Oza AM, Clarke BA, Mackay HJ, et al
    Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31620.
    PubMed     Text format     Abstract available


  104. BERGAMINI A, Pisano C, Di Napoli M, Arenare L, et al
    Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    Gynecol Oncol. 2017;144:72-76.
    PubMed     Text format     Abstract available


    December 2016
  105. KESSOUS R, Laskov I, Abitbol J, Bitharas J, et al
    Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2016 Dec 29. pii: S0090-8258(16)31679.
    PubMed     Text format     Abstract available


  106. PIULATS JM, Guerra E, Gil-Martin M, Roman-Canal B, et al
    Molecular approaches for classifying endometrial carcinoma.
    Gynecol Oncol. 2016 Dec 28. pii: S0090-8258(16)31680.
    PubMed     Text format     Abstract available


  107. NAROD S, Sopik V
    Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
    Gynecol Oncol. 2016 Dec 22. pii: S0090-8258(16)31615.
    PubMed     Text format    


  108. DOLL KM, Pinheiro LC, Reeve BB
    Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
    Gynecol Oncol. 2016 Dec 14. pii: S0090-8258(16)31623.
    PubMed     Text format     Abstract available


  109. RUBERG JL, Helm CW, Felleman BI, Helm JE, et al
    Is attendance at an ovarian cancer screening clinic a worry-reducing event? Findings from pre- to post-screening.
    Gynecol Oncol. 2016 Dec 13. pii: S0090-8258(16)31616.
    PubMed     Text format     Abstract available


  110. PRENDERGAST EN, Holzapfel M, Mueller JJ, Leitao MM Jr, et al
    Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
    Gynecol Oncol. 2016 Dec 12. pii: S0090-8258(16)31622.
    PubMed     Text format     Abstract available


  111. MARU Y, Tanaka N, Ohira M, Itami M, et al
    Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
    Gynecol Oncol. 2016 Dec 8. pii: S0090-8258(16)31614.
    PubMed     Text format     Abstract available


  112. RZEPECKA IK, Szafron LM, Stys A, Felisiak-Golabek A, et al
    Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    Gynecol Oncol. 2016 Dec 7. pii: S0090-8258(16)31597.
    PubMed     Text format     Abstract available


  113. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31497.
    PubMed     Text format     Abstract available


  114. MUSA F, Pothuri B, Blank SV, Ling HT, et al
    Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31612.
    PubMed     Text format     Abstract available


  115. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).
    Gynecol Oncol. 2016 Dec 2. pii: S0090-8258(16)31575.
    PubMed     Text format     Abstract available


  116. GILL SE, McGree ME, Weaver AL, Cliby WA, et al
    Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gynecol Oncol. 2016 Dec 1. pii: S0090-8258(16)31577.
    PubMed     Text format     Abstract available


    November 2016
  117. SEAGLE BL, Butler SK, Strohl AE, Nieves-Neira W, et al
    Chemotherapy delay after primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31578.
    PubMed     Text format     Abstract available


  118. NASIOUDIS D, Chapman-Davis E, Witkin SS, Holcomb K, et al
    Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31607.
    PubMed     Text format     Abstract available


  119. KARNEZIS AN, Cho KR
    Of mice and women - Non-ovarian origins of "ovarian" cancer.
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31608.
    PubMed     Text format    


  120. DE DECKER K, Speth S, Ter Brugge HG, Bart J, et al
    Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease.
    Gynecol Oncol. 2016 Nov 23. pii: S0090-8258(16)31604.
    PubMed     Text format     Abstract available


  121. CHENG A, Li M, Kanis MJ, Xu Y, et al
    Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis.
    Gynecol Oncol. 2016 Nov 23. pii: S0090-8258(16)31518.
    PubMed     Text format     Abstract available


  122. SORIO R, Roemer-Becuwe C, Hilpert F, Gibbs E, et al
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31562.
    PubMed     Text format     Abstract available


  123. HALTIA UM, Hallamaa M, Tapper J, Hynninen J, et al
    Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31574.
    PubMed     Text format     Abstract available


  124. HEITZ F, Hengsbach A, Harter P, Traut A, et al
    Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2016 Nov 16. pii: S0090-8258(16)31567.
    PubMed     Text format     Abstract available


  125. CORDEIRO VIDAL G, Babin G, Querleu D, Guyon F, et al
    Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31507.
    PubMed     Text format     Abstract available


  126. LI Y, Zhang HL, Kang S, Zhou RM, et al
    The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31566.
    PubMed     Text format     Abstract available


  127. HANNIBAL CG, Vang R, Junge J, Frederiksen K, et al
    A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31563.
    PubMed     Text format     Abstract available


  128. MARCHETTI C, Kristeleit R, McCormack M, Mould T, et al
    Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
    Gynecol Oncol. 2016 Nov 5. pii: S0090-8258(16)31520.
    PubMed     Text format     Abstract available


  129. DAHM-KAHLER P, Borgfeldt C, Holmberg E, Staf C, et al
    Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
    Gynecol Oncol. 2016 Nov 3. pii: S0090-8258(16)31516.
    PubMed     Text format     Abstract available


    October 2016
  130. DESALE MG, Tanner EJ 3rd, Sinno AK, Angarita AA, et al
    Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2016 Oct 28. pii: S0090-8258(16)31501.
    PubMed     Text format     Abstract available


  131. HAGEN B, Valla M, Aune G, Ravlo M, et al
    Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm.
    Gynecol Oncol. 2016 Oct 21. pii: S0090-8258(16)31506.
    PubMed     Text format     Abstract available


  132. CHAN JK, Java JJ, Fuh K, Monk BJ, et al
    The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG oncology/gynecologic oncology group trials.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31421.
    PubMed     Text format     Abstract available


  133. LEE JY, Kim K, Lee YS, Kim HY, et al
    Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31498.
    PubMed     Text format     Abstract available


  134. GUELI ALLETTI S, Petrillo M, Vizzielli G, Bottoni C, et al
    Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
    Gynecol Oncol. 2016 Oct 18. pii: S0090-8258(16)31491.
    PubMed     Text format     Abstract available


  135. SEAGLE BL, Dayno M, Strohl AE, Graves S, et al
    Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
    Gynecol Oncol. 2016 Oct 16. pii: S0090-8258(16)31495.
    PubMed     Text format     Abstract available


  136. CRAIG ER, Londono AI, Norian LA, Arend RC, et al
    Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.
    Gynecol Oncol. 2016 Oct 14. pii: S0090-8258(16)31477.
    PubMed     Text format     Abstract available


  137. KIM HS, Bristow RE, Chang SJ
    Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31488.
    PubMed     Text format     Abstract available


  138. LEBLANC E, Narducci F, Bresson L, Hudry D, et al
    Fluorescence-assisted sentinel (SND) and pelvic node dissections by single-port transvaginal laparoscopic surgery, for the management of an endometrial carcinoma (EC) in an elderly obese patient.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31482.
    PubMed     Text format     Abstract available


  139. BAI H, Cao D, Yuan F, Sha G, et al
    Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31481.
    PubMed     Text format     Abstract available


  140. SOLIMAN PT, Zhang Q, Broaddus RR, Westin SN, et al
    Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31483.
    PubMed     Text format     Abstract available


  141. FADER AN, Java J, Tenney M, Ricci S, et al
    Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.
    Gynecol Oncol. 2016 Oct 12. pii: S0090-8258(16)31490.
    PubMed     Text format     Abstract available


  142. BRYK S, Farkkila A, Butzow R, Leminen A, et al
    Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2016 Oct 8. pii: S0090-8258(16)31473.
    PubMed     Text format     Abstract available


  143. GARCIA-SOTO AE, Java JJ, Nieves Neira W, Pearson JM, et al
    Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31474.
    PubMed     Text format     Abstract available


  144. LIAO Y, Deng Y, Liu J, Ye Z, et al
    MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31410.
    PubMed     Text format     Abstract available


  145. SHAFRIR AL, Rice MS, Gupta M, Terry KL, et al
    The association between reproductive and hormonal factors and ovarian cancer by estrogen-alpha and progesterone receptor status.
    Gynecol Oncol. 2016 Oct 5. pii: S0090-8258(16)31430.
    PubMed     Text format     Abstract available


  146. WRIGHT AA, Bohlke K, Armstrong DK, Bookman MA, et al
    Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Gynecol Oncol. 2016;143:3-15.
    PubMed     Text format     Abstract available


    September 2016
  147. MISHKIN G, Minasian LM, Kohn EC, Noone AM, et al
    The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.
    Gynecol Oncol. 2016 Sep 30. pii: S0090-8258(16)31432.
    PubMed     Text format     Abstract available


  148. AL-NIAIMI A, Dickson EL, Albertin C, Karnowski J, et al
    The impact of perioperative beta blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 29. pii: S0090-8258(16)31425.
    PubMed     Text format     Abstract available


  149. MUELLER JJ, Kelly A, Zhou Q, Iasonos A, et al
    Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Gynecol Oncol. 2016 Sep 28. pii: S0090-8258(16)31420.
    PubMed     Text format     Abstract available


  150. ROSE PG, Java JJ, Morgan MA, Alvarez-Secord A, et al
    Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2016 Sep 27. pii: S0090-8258(16)31368.
    PubMed     Text format     Abstract available


  151. OH J, Barve M, Matthews CM, Koon EC, et al
    Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Gynecol Oncol. 2016 Sep 24. pii: S0090-8258(16)31424.
    PubMed     Text format     Abstract available


  152. FU Y, Biglia N, Wang Z, Shen Y, et al
    Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.
    Gynecol Oncol. 2016 Sep 23. pii: S0090-8258(16)31427.
    PubMed     Text format     Abstract available


  153. WILBUR MB, Mannschreck DB, Angarita AM, Matsuno RK, et al
    Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology.
    Gynecol Oncol. 2016 Sep 21. pii: S0090-8258(16)31426.
    PubMed     Text format     Abstract available


  154. CAMPBELL G, Hagan T, Gilbertson-White S, Houze M, et al
    Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2016 Sep 18. pii: S0090-8258(16)31414.
    PubMed     Text format     Abstract available


  155. KATO K, Nomura H, Nagashima M, Takeshima N, et al
    Secondary debulking surgery for isolated pelvic nodal recurrence requiring external iliac vein excision and reconstruction in a patient with ovarian cancer.
    Gynecol Oncol. 2016 Sep 11. pii: S0090-8258(16)31411.
    PubMed     Text format     Abstract available


  156. HOGEN L, Thomas G, Bernardini M, Bassiouny D, et al
    The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 9. pii: S0090-8258(16)31369.
    PubMed     Text format     Abstract available


  157. PINSKY PF, Yu K, Kramer BS, Black A, et al
    Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31361.
    PubMed     Text format     Abstract available


  158. SINGH S, Guetzko M, Resnick K
    Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31367.
    PubMed     Text format     Abstract available


  159. ALHILLI MM, Becker MA, Weroha SJ, Flatten KS, et al
    In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 7. pii: S0090-8258(16)31355.
    PubMed     Text format     Abstract available


  160. MELAMED A, Hinchcliff EM, Clemmer JT, Bregar AJ, et al
    Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31365.
    PubMed     Text format     Abstract available


  161. NAKAYAMA M, Kobayashi H, Takahara T, Nishimura Y, et al
    A comparison of overall survival with 40 and 50mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31357.
    PubMed     Text format     Abstract available


  162. MANGILI G, Ottolina J, Cormio G, Loizzi V, et al
    Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study.
    Gynecol Oncol. 2016 Sep 3. pii: S0090-8258(16)31342.
    PubMed     Text format     Abstract available


    August 2016
  163. NASSER S, Lazaridis A, Evangelou M, Jones B, et al
    Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.
    Gynecol Oncol. 2016 Aug 29. pii: S0090-8258(16)31348.
    PubMed     Text format     Abstract available


  164. KALDAWY A, Segev Y, Lavie O, Auslender R, et al
    Low-grade serous ovarian cancer: A review.
    Gynecol Oncol. 2016 Aug 28. pii: S0090-8258(16)31346.
    PubMed     Text format     Abstract available


  165. MORSE CB, Norquist BM, Harrell MI, Agnew KJ, et al
    Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2016 Aug 27. pii: S0090-8258(16)31351.
    PubMed     Text format     Abstract available


  166. BRIGHTWELL RM, Grzankowski KS, Lele S, Eng K, et al
    The CD47 "don't eat me signal" is highly expressed in human ovarian cancer.
    Gynecol Oncol. 2016 Aug 25. pii: S0090-8258(16)31352.
    PubMed     Text format     Abstract available


  167. GERSHENSON DM, Frazier AL
    Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment.
    Gynecol Oncol. 2016 Aug 25. pii: S0090-8258(16)31354.
    PubMed     Text format     Abstract available


  168. PAIK ES, Shim M, Choi HJ, Lee YY, et al
    Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
    Gynecol Oncol. 2016 Aug 23. pii: S0090-8258(16)31347.
    PubMed     Text format     Abstract available


  169. RASMUSSEN CB, Jensen A, Albieri V, Andersen KK, et al
    Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study.
    Gynecol Oncol. 2016 Aug 20. pii: S0090-8258(16)31344.
    PubMed     Text format     Abstract available


  170. MONK BJ, Poveda A, Vergote I, Raspagliesi F, et al
    Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
    Gynecol Oncol. 2016 Aug 18. pii: S0090-8258(16)30983.
    PubMed     Text format     Abstract available


  171. UPPAL S, Rice LW, Beniwal A, Spencer RJ, et al
    Trends in hospice discharge, documented inpatient palliative care services and inpatient mortality in ovarian carcinoma.
    Gynecol Oncol. 2016 Aug 16. pii: S0090-8258(16)31261.
    PubMed     Text format     Abstract available


  172. SMITH B, Neff R, Cohn DE, Backes FJ, et al
    The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.
    Gynecol Oncol. 2016 Aug 15. pii: S0090-8258(16)31260.
    PubMed     Text format     Abstract available


  173. HAY CM, Courtney-Brooks M, Lefkowits C, Hagan TL, et al
    Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important?
    Gynecol Oncol. 2016 Aug 13. pii: S0090-8258(16)31258.
    PubMed     Text format     Abstract available


  174. TOZZI R, Traill Z, Garruto Campanile R, Ferrari F, et al
    Porta hepatis peritonectomy and hepato-celiac lymphadenectomy in patients with stage IIIC-IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes.
    Gynecol Oncol. 2016 Aug 9. pii: S0090-8258(16)31255.
    PubMed     Text format     Abstract available


  175. CHAO A, Wu RC, Jung SM, Lee YS, et al
    Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology.
    Gynecol Oncol. 2016 Aug 4. pii: S0090-8258(16)30985.
    PubMed     Text format     Abstract available


  176. ALETTI GD, Cliby WA
    Time for centralizing patients with ovarian cancer: what are we waiting for?
    Gynecol Oncol. 2016;142:209-10.
    PubMed     Text format    


    July 2016
  177. SANTOIEMMA PP, Reyes C, Wang LP, McLane MW, et al
    Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.
    Gynecol Oncol. 2016 Jul 25. pii: S0090-8258(16)30976.
    PubMed     Text format     Abstract available


  178. PETRICONE-WESTWOOD D, Lebel S
    Being a caregiver to patients with ovarian cancer: A scoping review of the literature.
    Gynecol Oncol. 2016 Jul 24. pii: S0090-8258(16)30876.
    PubMed     Text format     Abstract available


  179. KANSKA J, Zakhour M, Taylor-Harding B, Karlan BY, et al
    Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Jul 23. pii: S0090-8258(16)30982.
    PubMed     Text format     Abstract available


  180. WILSON AJ, Sarfo-Kantanka K, Barrack T, Steck A, et al
    Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
    Gynecol Oncol. 2016 Jul 19. pii: S0090-8258(16)30957.
    PubMed     Text format     Abstract available


  181. TOZZI R, Gubbala K, Majd HS, Campanile RG, et al
    Interval Laparoscopic En-Bloc Resection of the Pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: Description of the technique and surgical outcomes.
    Gynecol Oncol. 2016 Jul 19. pii: S0090-8258(16)30837.
    PubMed     Text format     Abstract available


  182. GAO B, Lindemann K, Anderson L, Fereday S, et al
    Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
    Gynecol Oncol. 2016 Jul 18. pii: S0090-8258(16)30834.
    PubMed     Text format     Abstract available


  183. BROWN AJ, Shen MJ, Urbauer D, Taylor J, et al
    Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients.
    Gynecol Oncol. 2016 Jul 18. pii: S0090-8258(16)30879.
    PubMed     Text format     Abstract available


  184. MOGENSEN JB, Kjaer SK, Mellemkjaer L, Jensen A, et al
    Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study.
    Gynecol Oncol. 2016 Jul 15. pii: S0090-8258(16)30964.
    PubMed     Text format     Abstract available


  185. WANG D, Li C, Zhang Y, Wang M, et al
    Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30961.
    PubMed     Text format     Abstract available


  186. GUNDERSON CC, Ding K, Dvorak J, Moore KN, et al
    The pro-inflammatory effect of obesity on high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30972.
    PubMed     Text format     Abstract available


  187. CHAN JK, Gardner AB, Chan JE, Guan A, et al
    The influence of age and other prognostic factors associated with survival of ovarian immature teratoma - A study of 1307 patients.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30835.
    PubMed     Text format     Abstract available


  188. WATSON CH, Ulm M, Blackburn P, Smiley L, et al
    Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma.
    Gynecol Oncol. 2016 Jul 11. pii: S0090-8258(16)30963.
    PubMed     Text format     Abstract available


  189. DE LA MOTTE ROUGE T, Pautier P, Genestie C, Rey A, et al
    Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.
    Gynecol Oncol. 2016 Jul 8. pii: S0090-8258(16)30862.
    PubMed     Text format     Abstract available


  190. MARTIN JY, Goff BA, Urban RR
    Preoperative hyponatremia in women with ovarian cancer: An additional cause for concern?
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30829.
    PubMed     Text format     Abstract available


  191. GIANNAKEAS V, Sopik V, Narod SA
    A model for ovarian cancer progression based on inherent resistance.
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30825.
    PubMed     Text format     Abstract available


  192. WALKER JL
    Intraperitoneal chemotherapy for ovarian cancer.
    Gynecol Oncol. 2016;142:1-2.
    PubMed     Text format    


    June 2016
  193. DE LEON M, Cardenas H, Vieth E, Emerson R, et al
    Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30828.
    PubMed     Text format     Abstract available


  194. SZUBERT S, Wojtowicz A, Moszynski R, Zywica P, et al
    External validation of the IOTA ADNEX model performed by two independent gynecologic centers.
    Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30831.
    PubMed     Text format     Abstract available


  195. ATASEVEN B, Chiva LM, Harter P, Gonzalez-Martin A, et al
    FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited.
    Gynecol Oncol. 2016 Jun 19. pii: S0090-8258(16)30824.
    PubMed     Text format     Abstract available


  196. RAUH-HAIN JA, Birrer M, Del Carmen MG
    "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
    Gynecol Oncol. 2016 Jun 16. pii: S0090-8258(16)30771.
    PubMed     Text format     Abstract available


  197. ROQUE DR, Makowski L, Chen TH, Rashid N, et al
    Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project.
    Gynecol Oncol. 2016 Jun 8. pii: S0090-8258(16)30811.
    PubMed     Text format     Abstract available


  198. ANDRIKOPOULOU M, Vetere P, Nezhat FR
    Ovarian cancer laparoscopic hysterectomy and staging in a patient with history of intraperitoneal renal transplant.
    Gynecol Oncol. 2016 Jun 7. pii: S0090-8258(16)30812.
    PubMed     Text format     Abstract available


  199. HIJAZ M, Chhina J, Mert I, Taylor M, et al
    Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Gynecol Oncol. 2016 Jun 6. pii: S0090-8258(16)30773.
    PubMed     Text format     Abstract available


  200. TSENG JH, Suidan RS, Zivanovic O, Gardner GJ, et al
    Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes.
    Gynecol Oncol. 2016 Jun 4. pii: S0090-8258(16)30764.
    PubMed     Text format     Abstract available


  201. SAWYER BT, LaFargue CJ, Bristow RE
    Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30769.
    PubMed     Text format     Abstract available


  202. BARBER EL, Rutstein SE, Miller WC, Gehrig PA, et al
    Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30767.
    PubMed     Text format    


  203. ESSELEN KM, Terry KL, Samuel A, Elias KM, et al
    Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery?
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30765.
    PubMed     Text format     Abstract available


  204. WRIGHT JD, Chen L, Jorge S, Burke WM, et al
    Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery.
    Gynecol Oncol. 2016;141:531-7.
    PubMed     Text format     Abstract available


    May 2016
  205. GOUY S, Ferron G, Glehen O, Bayar A, et al
    Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30760.
    PubMed     Text format     Abstract available


  206. HERNANDEZ L, Kim MK, Lyle LT, Bunch KP, et al
    Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30757.
    PubMed     Text format     Abstract available


  207. DAHM-KAHLER P, Palmqvist C, Staf C, Holmberg E, et al
    Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - a population-based cohort study.
    Gynecol Oncol. 2016 May 26. pii: S0090-8258(16)30754.
    PubMed     Text format     Abstract available


  208. KUMAR A, Moynagh MR, Multinu F, Cliby WA, et al
    Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
    Gynecol Oncol. 2016 May 25. pii: S0090-8258(16)30756.
    PubMed     Text format     Abstract available


  209. JORGE S, Jones NL, Chen L, Hou JY, et al
    Characteristics, treatment and outcomes of women with immature ovarian Teratoma, 1998-2012.
    Gynecol Oncol. 2016 May 21. pii: S0090-8258(16)30753.
    PubMed     Text format     Abstract available


  210. PETRILLO M, Amadio G, Salutari V, Paris I, et al
    Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
    Gynecol Oncol. 2016 May 20. pii: S0090-8258(16)30741.
    PubMed     Text format     Abstract available


  211. ATASEVEN B, Harter P, Grimm C, Heitz F, et al
    The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30745.
    PubMed     Text format     Abstract available


  212. SLAUGHTER K, Holman LL, Thomas EL, Gunderson CC, et al
    Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30744.
    PubMed     Text format     Abstract available


  213. DAI D, Thiel KW, Salinas EA, Goodheart MJ, et al
    Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.
    Gynecol Oncol. 2016 May 16. pii: S0090-8258(16)30731.
    PubMed     Text format     Abstract available


  214. POOLE EM, Konstantinopoulos PA, Terry KL
    Prognostic implications of reproductive and lifestyle factors in ovarian cancer.
    Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30733.
    PubMed     Text format     Abstract available


  215. SCHLAPPE BA, Mueller JJ, Zivanovic O, Gardner GJ, et al
    Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30734.
    PubMed     Text format     Abstract available


  216. HUSAIN A, Wang Y, Hanker LC, Ojeda B, et al
    Independent Radiologic Review of AURELIA, A Phase 3 Trial of Bevacizumab Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer.
    Gynecol Oncol. 2016 May 13. pii: S0090-8258(16)30730.
    PubMed     Text format     Abstract available


  217. TURNER TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, et al
    Ovarian cancer and the immune system - The role of targeted therapies.
    Gynecol Oncol. 2016 May 9. pii: S0090-8258(16)30686.
    PubMed     Text format     Abstract available


  218. VATANSEVER D, Atici AE, Sozen H, Sakin O, et al
    Diaphragmatic resection preserving and repairing pericardium, splenectomy and distal pancreatectomy for interval debulking surgery of ovarian cancer.
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30682.
    PubMed     Text format     Abstract available


  219. KARLSEN NM, Karlsen MA, Hogdall E, Nedergaard L, et al
    Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT).
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30684.
    PubMed     Text format     Abstract available


  220. XIONG J, He M, Hansen K, Jackson CL, et al
    The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma.
    Gynecol Oncol. 2016 May 3. pii: S0090-8258(16)30679.
    PubMed     Text format     Abstract available


  221. ZHANG D, Bai B, Xi Y, Wang T, et al
    Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis.
    Gynecol Oncol. 2016 May 2. pii: S0090-8258(16)30677.
    PubMed     Text format     Abstract available


  222. HOLLESTELLE A, van der Baan FH, Berchuck A, Johnatty SE, et al
    No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
    Gynecol Oncol. 2016;141:386-401.
    PubMed     Text format     Abstract available


    April 2016
  223. SUH DH, Kim HS, Chang SJ, Bristow RE, et al
    Surgical management of recurrent ovarian cancer.
    Gynecol Oncol. 2016 Apr 26. pii: S0090-8258(16)30164.
    PubMed     Text format     Abstract available


  224. SZENDER JB, Eng KH, Matsuzaki J, Miliotto A, et al
    HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.
    Gynecol Oncol. 2016 Apr 22. pii: S0090-8258(16)30150.
    PubMed     Text format     Abstract available


  225. STROHL AE, Feinglass JM, Shahabi S, Simon MA, et al
    Surgical wait time: A new health indicator in women with endometrial cancer.
    Gynecol Oncol. 2016 Apr 22. pii: S0090-8258(16)30146.
    PubMed     Text format     Abstract available


  226. SHALOWITZ DI, Epstein AJ, Ko EM, Giuntoli RL 2nd, et al
    Non-surgical management of ovarian cancer: Prevalence and implications.
    Gynecol Oncol. 2016 Apr 20. pii: S0090-8258(16)30158.
    PubMed     Text format     Abstract available


  227. RODRIGUEZ GC, Turbov J, Rosales R, Yoo J, et al
    Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.
    Gynecol Oncol. 2016 Apr 19. pii: S0090-8258(16)30154.
    PubMed     Text format     Abstract available


  228. WALLBILLICH JJ, Forde B, Havrilesky LJ, Cohn DE, et al
    A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
    Gynecol Oncol. 2016 Apr 19. pii: S0090-8258(16)30156.
    PubMed     Text format     Abstract available


  229. VIZZIELLI G, Costantini B, Tortorella L, Pitruzzella I, et al
    A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment.
    Gynecol Oncol. 2016 Apr 18. pii: S0090-8258(16)30152.
    PubMed     Text format     Abstract available


  230. FENG Z, Wen H, Bi R, Yang W, et al
    Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Apr 17. pii: S0090-8258(16)30148.
    PubMed     Text format     Abstract available


  231. NAROD SA
    Talc and ovarian cancer.
    Gynecol Oncol. 2016 Apr 16. pii: S0090-8258(16)30139.
    PubMed     Text format    


  232. EGGINK FA, Mom CH, Kruitwagen RF, Reyners AK, et al
    Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.
    Gynecol Oncol. 2016 Apr 15. pii: S0090-8258(16)30140.
    PubMed     Text format     Abstract available


  233. ZHOU Y, Irwin ML, Ferrucci LM, McCorkle R, et al
    Health-related quality of life in ovarian cancer survivors: Results from the American Cancer Society's Study of Cancer Survivors - I.
    Gynecol Oncol. 2016 Apr 9. pii: S0090-8258(16)30106.
    PubMed     Text format     Abstract available


  234. KOBEL M, Atenafu EG, Rambau PF, Ferguson SE, et al
    Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Gynecol Oncol. 2016 Apr 9. pii: S0090-8258(16)30109.
    PubMed     Text format     Abstract available


  235. ZHU X, Lang J
    The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review.
    Gynecol Oncol. 2016 Apr 7. pii: S0090-8258(16)30103.
    PubMed     Text format     Abstract available


  236. DORAYAPPAN KD, Wallbillich JJ, Cohn DE, Selvendiran K, et al
    The biological significance and clinical applications of exosomes in ovarian cancer.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30092.
    PubMed     Text format     Abstract available


  237. PETRILLO M, Nero C, Amadio G, Gallo D, et al
    Targeting the hallmarks of ovarian cancer: The big picture.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30093.
    PubMed     Text format     Abstract available


  238. NOER MC, Sperling CD, Antonsen SL, Ottesen B, et al
    A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30090.
    PubMed     Text format     Abstract available


  239. ALVAREZ RD, Matulonis UA, Herzog TJ, Coleman RL, et al
    Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
    Gynecol Oncol. 2016 Apr 3. pii: S0090-8258(16)30063.
    PubMed     Text format    


  240. WINTERHOFF B, Hamidi H, Wang C, Kalli KR, et al
    Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.
    Gynecol Oncol. 2016;141:95-100.
    PubMed     Text format     Abstract available


  241. ZHANG M, Liu G, Xue F, Edwards R, et al
    Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    Gynecol Oncol. 2016;141:57-64.
    PubMed     Text format     Abstract available


  242. MURAKAMI R, Matsumura N, Brown JB, Wang Z, et al
    Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.
    Gynecol Oncol. 2016;141:49-56.
    PubMed     Text format     Abstract available


  243. TINQUAUT F, Freyer G, Chauvin F, Gane N, et al
    Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials.
    Gynecol Oncol. 2016 Apr 1. pii: S0090-8258(16)30074.
    PubMed     Text format     Abstract available


  244. MUNKARAH A, Mert I, Chhina J, Hamid S, et al
    Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.
    Gynecol Oncol. 2016;141:72-9.
    PubMed     Text format     Abstract available


  245. JANCO JM, Kumar A, Weaver AL, McGree ME, et al
    Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
    Gynecol Oncol. 2016;141:140-7.
    PubMed     Text format     Abstract available


    March 2016
  246. KIM TH, Kim HS, Kim TJ, Chang SJ, et al
    Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis.
    Gynecol Oncol. 2016 Mar 25. pii: S0090-8258(16)30087.
    PubMed     Text format     Abstract available


  247. SHARROW AC, Perkins B, Collector MI, Yu W, et al
    Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy.
    Gynecol Oncol. 2016 Mar 24. pii: S0090-8258(16)30077.
    PubMed     Text format     Abstract available


  248. GHEZZI F, Cromi A, Fanfani F, Malzoni M, et al
    Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: a multi-institutional experience.
    Gynecol Oncol. 2016 Mar 24. pii: S0090-8258(16)30086.
    PubMed     Text format     Abstract available


  249. YANARANOP M, Tiyayon J, Siricharoenthai S, Nakrangsee S, et al
    Rajavithi-ovarian cancer predictive score (R-OPS): A new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass.
    Gynecol Oncol. 2016 Mar 17. pii: S0090-8258(16)30075.
    PubMed     Text format     Abstract available


  250. HEITZ F, Harter P, Alesina PF, Walz MK, et al
    Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery.
    Gynecol Oncol. 2016 Mar 11. pii: S0090-8258(16)30070.
    PubMed     Text format     Abstract available


  251. WITKOWSKI L, Goudie C, Ramos P, Boshari T, et al
    The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
    Gynecol Oncol. 2016 Mar 11. pii: S0090-8258(16)30071.
    PubMed     Text format     Abstract available


  252. DAO F, Schlappe BA, Tseng J, Lester J, et al
    Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2016 Mar 11. pii: S0090-8258(16)30067.
    PubMed     Text format     Abstract available


  253. PRADER S, Harter P, Grimm C, Traut A, et al
    Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer.
    Gynecol Oncol. 2016 Mar 10. pii: S0090-8258(16)30069.
    PubMed     Text format     Abstract available


  254. WEBB JR, Milne K, Kroeger DR, Nelson BH, et al
    PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2016 Mar 10. pii: S0090-8258(16)30065.
    PubMed     Text format     Abstract available


  255. MILLER KR, Patel JN, Ganapathi MK, Tait DL, et al
    Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer.
    Gynecol Oncol. 2016 Mar 5. pii: S0090-8258(16)30061.
    PubMed     Text format     Abstract available


  256. BACKES FJ, Walker CJ, Goodfellow PJ, Hade EM, et al
    Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.
    Gynecol Oncol. 2016 Mar 5. pii: S0090-8258(16)30062.
    PubMed     Text format     Abstract available


  257. SMITH JA, Mathew L, Burney M, Nyshadham P, et al
    Equivalency challenge: Evaluation of lipodox(R) as the generic equivalent for doxil(R) in a human ovarian cancer orthotropic mouse model.
    Gynecol Oncol. 2016 Mar 2. pii: S0090-8258(16)30057.
    PubMed     Text format     Abstract available


  258. DELGADO E, Boisen MM, Laskey R, Chen R, et al
    High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.
    Gynecol Oncol. 2016 Mar 2. pii: S0090-8258(16)30054.
    PubMed     Text format     Abstract available


    February 2016
  259. NAROD SA, Sopik V, Giannakeas V
    Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.
    Gynecol Oncol. 2016 Feb 25. pii: S0090-8258(16)30044.
    PubMed     Text format    


  260. COX BAUER CM, Greer DM, Kram JJ, Kamelle SA, et al
    Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer.
    Gynecol Oncol. 2016 Feb 25. pii: S0090-8258(16)30041.
    PubMed     Text format     Abstract available


  261. CHUNDURY A, Apicelli A, DeWees T, Powell M, et al
    Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy.
    Gynecol Oncol. 2016 Feb 10. pii: S0090-8258(16)30031.
    PubMed     Text format     Abstract available


  262. SIMONE CG, Markham MJ, Dizon DS
    Chemotherapy in ovarian germ cell tumors: A systematic review.
    Gynecol Oncol. 2016 Feb 9. pii: S0090-8258(16)30033.
    PubMed     Text format     Abstract available


  263. NASIOUDIS D, Sisti G, Kanninen TT, Holcomb K, et al
    Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study.
    Gynecol Oncol. 2016 Feb 8. pii: S0090-8258(16)30030.
    PubMed     Text format     Abstract available


  264. BRADFORD A, Shinn E
    Incorporating Patient Perspectives and Priorities into Clinical Trial Design.
    Gynecol Oncol. 2016;140:191-2.
    PubMed     Text format    


    January 2016
  265. KONECNY GE, Winterhoff B, Wang C
    Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification.
    Gynecol Oncol. 2016 Jan 28. pii: S0090-8258(16)30024.
    PubMed     Text format     Abstract available


  266. GREGGI S, Falcone F, Carputo R, Raspagliesi F, et al
    Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
    Gynecol Oncol. 2016 Jan 26. pii: S0090-8258(16)30023.
    PubMed     Text format     Abstract available


  267. YOSHIDA A, Derchain SF, Pitta DR, De Angelo Andrade LA, et al
    Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?
    Gynecol Oncol. 2016 Jan 26. pii: S0090-8258(16)30021.
    PubMed     Text format     Abstract available


  268. GRABOWSKI JP, Harter P, Heitz F, Pujade-Lauraine E, et al
    Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
    Gynecol Oncol. 2016 Jan 22. pii: S0090-8258(16)30020.
    PubMed     Text format     Abstract available


  269. WESTIN SN, Randall L
    The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topics.
    Gynecol Oncol. 2016 Jan 22. pii: S0090-8258(16)00040.
    PubMed     Text format    


  270. GUELI ALLETTI S, Rossitto C, Cianci S, Scambia G, et al
    Telelap ALF-X total hysterectomy for early stage endometrial cancer: New frontier of robotic gynecological surgery.
    Gynecol Oncol. 2016 Jan 21. pii: S0090-8258(16)30018.
    PubMed     Text format    


  271. ROMAGNOLO C, Leon AE, Fabricio AS, Taborelli M, et al
    HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Gynecol Oncol. 2016 Jan 19. pii: S0090-8258(16)30015.
    PubMed     Text format     Abstract available


  272. KATO K, Katsuda T, Takeshima N
    Cytoreduction of diaphragmatic metastasis from ovarian cancer with involvement of the liver using a ventral liver mobilization technique.
    Gynecol Oncol. 2016 Jan 19. pii: S0090-8258(16)30017.
    PubMed     Text format     Abstract available


  273. WEBERPALS JI, Amin MS, Chen BE, Tu D, et al
    First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16.
    Gynecol Oncol. 2016 Jan 13. pii: S0090-8258(16)30013.
    PubMed     Text format     Abstract available


  274. WOOPEN H, Richter R, Ismaeel F, Chekerov R, et al
    The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
    Gynecol Oncol. 2016 Jan 11. pii: S0090-8258(16)30012.
    PubMed     Text format     Abstract available


  275. MUELLER JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, et al
    Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Gynecol Oncol. 2016 Jan 9. pii: S0090-8258(16)30008.
    PubMed     Text format     Abstract available


  276. HINCHCLIFF E, Rauh-Hain JA, Clemmer JT, Diver E, et al
    Racial disparities in survival in malignant germ cell tumors of the ovary.
    Gynecol Oncol. 2016 Jan 7. pii: S0090-8258(16)30006.
    PubMed     Text format     Abstract available


  277. LU L, Katsaros D, Canuto EM, Biglia N, et al
    LIN-28B/let-7a/IGF-II Axis Molecular Subtypes are Associated with Epithelial Ovarian Cancer Prognosis.
    Gynecol Oncol. 2016 Jan 2. pii: S0090-8258(15)30238.
    PubMed     Text format     Abstract available


  278. JOHANSEN N, Liavaag AH, Tanbo TG, Dahl AA, et al
    Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
    Gynecol Oncol. 2016;140:101-6.
    PubMed     Text format     Abstract available


  279. PRESCOTT LS, Dickens AS, Guerra SL, Tanha JM, et al
    Fighting cancer together: Development and implementation of shared medical appointments to standardize and improve chemotherapy education.
    Gynecol Oncol. 2016;140:114-9.
    PubMed     Text format     Abstract available


    December 2015
  280. WONG A, Kuick CH, Wong WL, Tham JM, et al
    Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with Grade 3 endometrioid endometrial carcinomas.
    Gynecol Oncol. 2015 Dec 31. pii: S0090-8258(15)30234.
    PubMed     Text format     Abstract available


  281. ERIKSSON AG, Ducie J, Ali N, McGree ME, et al
    Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion.
    Gynecol Oncol. 2015 Dec 30. pii: S0090-8258(15)30231.
    PubMed     Text format     Abstract available


  282. URBAN RR, He H, Alfonso R, Hardesty MM, et al
    Ovarian cancer outcomes: Predictors of early death.
    Gynecol Oncol. 2015 Dec 29. pii: S0090-8258(15)30224.
    PubMed     Text format     Abstract available


  283. HARTER P, Johnson T, Berton-Rigaud D, Park SY, et al
    BRCA1/2 Mutations Associated with Progression-Free Survival in Ovarian Cancer Patients in the AGO-OVAR 16 Study.
    Gynecol Oncol. 2015 Dec 28. pii: S0090-8258(15)30230.
    PubMed     Text format     Abstract available


  284. VAN DER STEEN SC, van Tilborg AA, Vallen MJ, Bulten J, et al
    Prognostic significance of highly sulfated chondroitin sulfates in ovarian cancer defined by the single chain antibody GD3A11.
    Gynecol Oncol. 2015 Dec 27. pii: S0090-8258(15)30227.
    PubMed     Text format     Abstract available


  285. EMONS G, Kurzeder C, Schmalfeldt B, Neuser P, et al
    Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-Study Group (AGO-GYN8).
    Gynecol Oncol. 2015 Dec 27. pii: S0090-8258(15)30229.
    PubMed     Text format     Abstract available


  286. BOAC BM, Xiong Y, Marchion DC, Abbasi F, et al
    Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.
    Gynecol Oncol. 2015 Dec 27. pii: S0090-8258(15)30228.
    PubMed     Text format     Abstract available


  287. DOMCHEK SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, et al
    Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
    Gynecol Oncol. 2015 Dec 23. pii: S0090-8258(15)30223.
    PubMed     Text format     Abstract available


  288. TAUBE ET, Denkert C, Sehouli J, Kunze CA, et al
    Wilms tumor protein 1 (WT1) - Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2015 Dec 22. pii: S0090-8258(15)30221.
    PubMed     Text format     Abstract available


  289. BERNARDS SS, Norquist BM, Harrell MI, Agnew KJ, et al
    Genetic characterization of early onset ovarian carcinoma.
    Gynecol Oncol. 2015 Dec 21. pii: S0090-8258(15)30220.
    PubMed     Text format     Abstract available


  290. CHEN X, Gong L, Ou R, Zheng Z, et al
    Sequential combination therapy of ovarian cancer with cisplatin and gamma-secretase inhibitor MK-0752.
    Gynecol Oncol. 2015 Dec 15. pii: S0090-8258(15)30215.
    PubMed     Text format     Abstract available


  291. ATASEVEN B, Grimm C, Harter P, Heitz F, et al
    Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30211.
    PubMed     Text format     Abstract available


  292. VOGEL TJ, Jeon C, Karlan B, Walsh C, et al
    Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30207.
    PubMed     Text format     Abstract available


  293. SOLEYMANI MAJD H, Ferrari F, Manek S, Gubbala K, et al
    Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during Visceral-Peritoneal Debulking (VPD) in 100 consecutive patients with stage IIIC-IV ovarian cancer: A surgical-histological analysis.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30208.
    PubMed     Text format     Abstract available


  294. NGUYEN TM, Shin IW, Lee TJ, Park J, et al
    Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30210.
    PubMed     Text format     Abstract available


  295. COOK LS, Leung AC, Swenerton K, Gallagher RP, et al
    Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study.
    Gynecol Oncol. 2015 Dec 12. pii: S0090-8258(15)30209.
    PubMed     Text format     Abstract available


    November 2015
  296. KIM KH, Jelovac D, Armstrong DK, Schwartz B, et al
    Phase 1b Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Epithelial Ovarian Cancer.
    Gynecol Oncol. 2015 Nov 28. pii: S0090-8258(15)30203.
    PubMed     Text format     Abstract available


  297. MINION LE, Coleman RL, Alvarez RD, Herzog TJ, et al
    Endpoints in clinical trials: What do patients consider important? A survey of the ovarian cancer national alliance.
    Gynecol Oncol. 2015 Nov 26. pii: S0090-8258(15)30202.
    PubMed     Text format     Abstract available


  298. VOS JR, Mourits MJ, Teixeira N, Jansen L, et al
    Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population.
    Gynecol Oncol. 2015 Nov 26. pii: S0090-8258(15)30201.
    PubMed     Text format     Abstract available


  299. SEROR J, Bats AS, Habchi H, Lecuru F, et al
    Optimal surgical cytoreduction of the upper abdomen and the diaphragm for advanced ovarian cancer using plasmajet energy.
    Gynecol Oncol. 2015 Nov 24. pii: S0090-8258(15)30200.
    PubMed     Text format     Abstract available


  300. CHEN CH, Shyu MK, Wang SW, Chou CH, et al
    MUC20 promotes aggressive phenotypes of epithelial ovarian cancer cells via activation of the integrin beta1 pathway.
    Gynecol Oncol. 2015 Nov 23. pii: S0090-8258(15)30197.
    PubMed     Text format     Abstract available


  301. BURTON ER, Brady M, Homesley HD, Rose PG, et al
    A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.
    Gynecol Oncol. 2015 Nov 23. pii: S0090-8258(15)30199.
    PubMed     Text format     Abstract available


  302. LANDRUM LM, Brady WE, Armstrong DK, Moore KN, et al
    A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2015 Nov 23. pii: S0090-8258(15)30196.
    PubMed     Text format     Abstract available


  303. RUTTEN IJ, van de Laar R, Kruitwagen RF, Bakers FC, et al
    Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography.
    Gynecol Oncol. 2015 Nov 19. pii: S0090-8258(15)30194.
    PubMed     Text format     Abstract available


  304. KOTSOPOULOS J, Rosen B, Fan I, Moody J, et al
    Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
    Gynecol Oncol. 2015 Nov 7. pii: S0090-8258(15)30181.
    PubMed     Text format     Abstract available


  305. KELEMEN LE, Warren GW, Koziak JM, Kobel M, et al
    Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer.
    Gynecol Oncol. 2015 Nov 5. pii: S0090-8258(15)30180.
    PubMed     Text format     Abstract available


  306. BOUCHARD-FORTIER G, Rosen B, Vyarvelska I, Pasetka M, et al
    A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Gynecol Oncol. 2015 Nov 4. pii: S0090-8258(15)30177.
    PubMed     Text format     Abstract available


  307. CALLEGARO-FILHO D, Gershenson DM, Nick AM, Munsell MF, et al
    Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
    Gynecol Oncol. 2015 Nov 4. pii: S0090-8258(15)30176.
    PubMed     Text format     Abstract available


  308. KUMAR A, Janco JM, Mariani A, Bakkum-Gamez JN, et al
    Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2015 Nov 2. pii: S0090-8258(15)30172.
    PubMed     Text format     Abstract available


  309. HASMAD HN, Lai KN, Wen WX, Park DJ, et al
    Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients.
    Gynecol Oncol. 2015 Nov 2. pii: S0090-8258(15)30173.
    PubMed     Text format     Abstract available


  310. NORQUIST BM, Swisher EM
    More genes, more problems? Benefits and risks of multiplex genetic testing.
    Gynecol Oncol. 2015;139:209-10.
    PubMed     Text format    


  311. CHOI HJ, Heo EJ, Paik E, Kim TJ, et al
    Laparo-endoscopic single site paraaortic lymphadenectomy facilitated by a new articulating vessel sealing device.
    Gynecol Oncol. 2015;139:385-6.
    PubMed     Text format    


  312. FREY MK, Kim SH, Bassett RY, Martineau J, et al
    Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.
    Gynecol Oncol. 2015;139:211-5.
    PubMed     Text format     Abstract available


    October 2015
  313. REYES HD, Carlson MJ, Devor EJ, Zhang Y, et al
    Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
    Gynecol Oncol. 2015 Oct 30. pii: S0090-8258(15)30170.
    PubMed     Text format     Abstract available


  314. BUAS MF, Gu H, Djukovic D, Zhu J, et al
    Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
    Gynecol Oncol. 2015 Oct 29. pii: S0090-8258(15)30168.
    PubMed     Text format     Abstract available


  315. TUULIA V, Anniina P, Annika A, Olli C, et al
    F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2015 Oct 26. pii: S0090-8258(15)30166.
    PubMed     Text format     Abstract available


  316. YANG YF, Liao YY, Liu XL, Su SG, et al
    Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment.
    Gynecol Oncol. 2015 Oct 19. pii: S0090-8258(15)30163.
    PubMed     Text format     Abstract available


  317. MIKAMI M, Tanabe K, Matsuo K, Miyazaki Y, et al
    Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma.
    Gynecol Oncol. 2015 Oct 18. pii: S0090-8258(15)30161.
    PubMed     Text format     Abstract available


  318. CHEN X, Dong C, Law PT, Chan MT, et al
    MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
    Gynecol Oncol. 2015 Oct 16. pii: S0090-8258(15)30157.
    PubMed     Text format     Abstract available


  319. LHEUREUX S, Karakasis K, Harter P, Scott C, et al
    Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
    Gynecol Oncol. 2015 Oct 14. pii: S0090-8258(15)30159.
    PubMed     Text format     Abstract available


  320. CELIK M, Tasci T, Basaran D, Tulunay G, et al
    Step by step right upper quadrant cytoreduction guided by computed tomography in advanced ovarian cancer.
    Gynecol Oncol. 2015 Oct 8. pii: S0090-8258(15)30155.
    PubMed     Text format    


  321. HUANG T, Poole EM, Okereke OI, Kubzansky LD, et al
    Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies.
    Gynecol Oncol. 2015 Oct 8. pii: S0090-8258(15)30153.
    PubMed     Text format     Abstract available


  322. HESS LM, Huang HQ, Hanlon AL, Robinson WR, et al
    Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2015 Oct 8. pii: S0090-8258(15)30152.
    PubMed     Text format     Abstract available


  323. MANCHANDA R, Legood R, Pearce L, Menon U, et al
    Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
    Gynecol Oncol. 2015 Oct 2. pii: S0090-8258(15)30150.
    PubMed     Text format     Abstract available


  324. RAMIREZ PT
    Upping the ante in assessing the feasibility of surgical cytoreduction for advanced ovarian cancer: A modified laparoscopic Predictive Index score.
    Gynecol Oncol. 2015;139:1-2.
    PubMed     Text format    


  325. SCHWAB CL, English DP, Black J, Bellone S, et al
    Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.
    Gynecol Oncol. 2015;139:112-7.
    PubMed     Text format     Abstract available


  326. NOVAK M, Lester J, Karst AM, Parkash V, et al
    Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.
    Gynecol Oncol. 2015;139:104-11.
    PubMed     Text format     Abstract available


    September 2015
  327. BARBER EL, Rutstein S, Miller WC, Gehrig PA, et al
    A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery.
    Gynecol Oncol. 2015 Sep 29. pii: S0090-8258(15)30141.
    PubMed     Text format     Abstract available


  328. ANDERSEN CL, Eskelund CW, Siersma VD, Felding P, et al
    is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?
    Gynecol Oncol. 2015 Sep 22. pii: S0090-8258(15)30133.
    PubMed     Text format    


  329. O'HANLAN KA, Sten MS, O'Holleran MS, Ford NN, et al
    Infrarenal lymphadenectomy for gynecological malignancies: Two laparoscopic approaches.
    Gynecol Oncol. 2015 Sep 22. pii: S0090-8258(15)30135.
    PubMed     Text format     Abstract available


  330. SHU CA, Zhou Q, Jotwani AR, Iasonos A, et al
    Ovarian clear cell carcinoma, outcomes by stage: The MSK experience.
    Gynecol Oncol. 2015 Sep 21. pii: S0090-8258(15)30132.
    PubMed     Text format     Abstract available


  331. GALVAN-TURNER VB, Chang J, Ziogas A, Bristow RE, et al
    Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.
    Gynecol Oncol. 2015 Sep 17. pii: S0090-8258(15)30131.
    PubMed     Text format     Abstract available


  332. TRETARRE B, Molinie F, Woronoff AS, Bossard N, et al
    Ovarian cancer in France: Trends in incidence, mortality and survival, 1980-2012.
    Gynecol Oncol. 2015 Sep 14. pii: S0090-8258(15)30130.
    PubMed     Text format     Abstract available


  333. ENG KH, Hanlon BM, Bradley WH, Brian Szender J, et al
    Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
    Gynecol Oncol. 2015 Sep 14. pii: S0090-8258(15)30128.
    PubMed     Text format     Abstract available


  334. LOKICH E, Palisoul M, Romano N, Craig Miller M, et al
    Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.
    Gynecol Oncol. 2015 Sep 11. pii: S0090-8258(15)30127.
    PubMed     Text format     Abstract available


  335. ALTMAN AD, Ferguson SE, Atenafu EG, Kobel M, et al
    Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behaviour of high risk endometrial cancers.
    Gynecol Oncol. 2015 Sep 6. pii: S0090-8258(15)30119.
    PubMed     Text format     Abstract available


  336. BECKER JH, Ezendam NP, Boll D, van der Aa M, et al
    Effects of surgical volumes on the survival of endometrial carcinoma.
    Gynecol Oncol. 2015 Sep 5. pii: S0090-8258(15)30118.
    PubMed     Text format    


  337. LIU Z, Beach JA, Agadjanian H, Jia D, et al
    Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.
    Gynecol Oncol. 2015 Sep 5. pii: S0090-8258(15)30117.
    PubMed     Text format     Abstract available


  338. URBAN N, Hawley S, Janes H, Karlan BY, et al
    Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.
    Gynecol Oncol. 2015 Sep 3. pii: S0090-8258(15)30115.
    PubMed     Text format     Abstract available


  339. KASHIMA H, Wu RC, Wang Y, Sinno A, et al
    Laminin C1 Expression by Uterine Carcinoma Cells Is Associated with Tumor Progression.
    Gynecol Oncol. 2015 Sep 3. pii: S0090-8258(15)30116.
    PubMed     Text format     Abstract available


  340. GIANNAKEAS V, Sopik V, Shestopaloff K, Iqbal J, et al
    A Model for Estimating Ovarian Cancer Risk: Application for Preventive Oophorectomy.
    Gynecol Oncol. 2015 Sep 2. pii: S0090-8258(15)30112.
    PubMed     Text format     Abstract available


  341. CHEN J, Xi B, Zhao Y, Yu Y, et al
    Retraction notice to "High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer" [Gynecol. Oncol. 126 (2012) 109-117].
    Gynecol Oncol. 2015;138:764.
    PubMed     Text format    


  342. MEISEL JL, Woo KM, Sudarsan N, Eng J, et al
    Development of a risk stratification system to guide treatment for female germ cell tumors.
    Gynecol Oncol. 2015;138:566-72.
    PubMed     Text format     Abstract available


  343. FELIX AS, Scott McMeekin D, Mutch D, Walker JL, et al
    Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 Trial.
    Gynecol Oncol. 2015 Sep 1. pii: S0090-8258(15)30113.
    PubMed     Text format     Abstract available


  344. GARCIA C, Lyon L, Conell C, Littell RD, et al
    Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2015;138:723-6.
    PubMed     Text format     Abstract available


    August 2015
  345. NAKAMURA M, Ono YJ, Kanemura M, Tanaka T, et al
    Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
    Gynecol Oncol. 2015 Aug 31. pii: S0090-8258(15)30102.
    PubMed     Text format     Abstract available


  346. DUSKA LR, Java JJ, Cohn DE, Burger RA, et al
    Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
    Gynecol Oncol. 2015 Aug 31. pii: S0090-8258(15)30103.
    PubMed     Text format     Abstract available


  347. ELIAS KM, Emori MM, Papp E, MacDuffie E, et al
    Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research.
    Gynecol Oncol. 2015 Aug 29. pii: S0090-8258(15)30109.
    PubMed     Text format     Abstract available


  348. SEIFERT H, Georgiou A, Alexander H, McLachlan J, et al
    Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2015 Aug 26. pii: S0090-8258(15)30107.
    PubMed     Text format     Abstract available


  349. SMITH HJ, Walters Haygood CL, Arend RC, Leath CA 3rd, et al
    PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2015 Aug 21. pii: S0090-8258(15)30105.
    PubMed     Text format     Abstract available


  350. SMITS A, Smits E, Lopes A, Das N, et al
    Body Mass Index, Physical Activity and Quality of Life of Ovarian Cancer Survivors: Time to Get Moving? Two-centre study.
    Gynecol Oncol. 2015 Aug 17. pii: S0090-8258(15)30099.
    PubMed     Text format     Abstract available


  351. AGHAJANIAN C, Goff B, Nycum LR, Wang YV, et al
    Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2015 Aug 10. pii: S0090-8258(15)30098.
    PubMed     Text format     Abstract available


  352. SIAMAKPOUR-REIHANI S, Owzar K, Jiang C, Turner T, et al
    Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2015 Aug 7. pii: S0090-8258(15)30095.
    PubMed     Text format     Abstract available


  353. LHEUREUX S, Shaw PA, Karakasis K, Oza AM, et al
    Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
    Gynecol Oncol. 2015;138:235-7.
    PubMed     Text format    


  354. FOSSATI M, Buzzonetti A, Monego G, Catzola V, et al
    Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAMxanti-CD3).
    Gynecol Oncol. 2015;138:343-51.
    PubMed     Text format     Abstract available


  355. OZGUL N, Basaran D, Boyraz G, Salman MC, et al
    Hemostatic control of inferior vena cava with tape traction maneuver in the presence of bulky metastatic paraaortic lymph nodes.
    Gynecol Oncol. 2015;138:492-3.
    PubMed     Text format    


  356. WILSON MK, Fong P, Mesnage S, Chrystal K, et al
    Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up.
    Gynecol Oncol. 2015;138:285-91.
    PubMed     Text format     Abstract available


    July 2015
  357. MATSUO K, Ramzan AA, Gualtieri MR, Mhawech-Fauceglia P, et al
    Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia.
    Gynecol Oncol. 2015 Jul 31. pii: S0090-8258(15)30092.
    PubMed     Text format     Abstract available


  358. LI D, Ding CY, Qiu LH
    Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis.
    Gynecol Oncol. 2015 Jul 29. pii: S0090-8258(15)30093.
    PubMed     Text format     Abstract available


  359. NEFF R, Havrilesky LJ, Chino J, O'Malley DM, et al
    Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome.
    Gynecol Oncol. 2015 Jul 29. pii: S0090-8258(15)30064.
    PubMed     Text format     Abstract available


  360. CHAN JL, Letourneau J, Salem W, Cil AP, et al
    Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery.
    Gynecol Oncol. 2015 Jul 29. pii: S0090-8258(15)30090.
    PubMed     Text format     Abstract available


  361. NYMOEN DA, Hetland Falkenthal TE, Holth A, Siong OG, et al
    Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
    Gynecol Oncol. 2015 Jul 28. pii: S0090-8258(15)30091.
    PubMed     Text format     Abstract available


  362. FERRISS JS, Java JJ, Bookman MA, Fleming GF, et al
    Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study.
    Gynecol Oncol. 2015 Jul 26. pii: S0090-8258(15)30088.
    PubMed     Text format     Abstract available


  363. LIANG MI, ElNaggar AC, Nekkanti S, O'Malley DM, et al
    Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
    Gynecol Oncol. 2015 Jul 24. pii: S0090-8258(15)30081.
    PubMed     Text format     Abstract available


  364. PETRILLO M, Vizzielli G, Fanfani F, Gallotta V, et al
    Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept.
    Gynecol Oncol. 2015 Jul 18. pii: S0090-8258(15)30080.
    PubMed     Text format     Abstract available


  365. ZHANG Y, Goodfellow R, Li Y, Yang S, et al
    NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling.
    Gynecol Oncol. 2015 Jul 17. pii: S0090-8258(15)30084.
    PubMed     Text format     Abstract available


  366. BARGHOUT SH, Zepeda N, Vincent K, Azad AK, et al
    RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
    Gynecol Oncol. 2015 Jul 15. pii: S0090-8258(15)30070.
    PubMed     Text format     Abstract available


  367. LIN KY, Miller DS, Bailey AA, Andrews SJ, et al
    Ovarian involvement in endometrioid adenocarcinoma of uterus.
    Gynecol Oncol. 2015 Jul 14. pii: S0090-8258(15)30073.
    PubMed     Text format     Abstract available


  368. WOOPEN H, Richter R, Chekerov R, Siepmann T, et al
    The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological On
    Gynecol Oncol. 2015 Jul 13. pii: S0090-8258(15)30068.
    PubMed     Text format     Abstract available


  369. TZORTZATOS G, Andersson E, Soller M, Askmalm MS, et al
    The gynecological surveillance of women with Lynch syndrome in Sweden.
    Gynecol Oncol. 2015 Jul 12. pii: S0090-8258(15)30078.
    PubMed     Text format     Abstract available


  370. COHN DE, Havrilesky LJ, Osann K, Lipscomb J, et al
    Consensus in Controversy: The Modified Delphi Method Applied to Gynecologic Oncology Practice.
    Gynecol Oncol. 2015 Jul 12. pii: S0090-8258(15)30075.
    PubMed     Text format     Abstract available


  371. GRAYBILL W, Sood AK, Monk BJ, Coleman RL, et al
    State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer.
    Gynecol Oncol. 2015 Jul 9. pii: S0090-8258(15)00984.
    PubMed     Text format    


  372. ATASEVEN B, du Bois A, Reinthaller A, Traut A, et al
    Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
    Gynecol Oncol. 2015 Jul 8. pii: S0090-8258(15)30067.
    PubMed     Text format     Abstract available


  373. FUH KC, Secord AA, Bevis KS, Huh W, et al
    Comparison of Bevacizumab Alone or with Chemotherapy in Recurrent Ovarian Cancer Patients.
    Gynecol Oncol. 2015 Jul 2. pii: S0090-8258(15)30062.
    PubMed     Text format     Abstract available


  374. ZIGHELBOIM I, Ali S, Lankes HA, Backes F, et al
    Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2015 Jul 2. pii: S0090-8258(15)30059.
    PubMed     Text format     Abstract available


  375. FEBBRARO T, Robison K, Wilbur JS, Laprise J, et al
    Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.
    Gynecol Oncol. 2015;138:109-14.
    PubMed     Text format     Abstract available


  376. BONNETERRE J, Hutt E, Bosq J, Graham JD, et al
    Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Gynecol Oncol. 2015 Jul 1. pii: S0090-8258(15)30058.
    PubMed     Text format     Abstract available


    June 2015
  377. VAN KRUCHTEN M, van der Marel P, de Munck L, Hollema H, et al
    Hormone Receptors as a Marker of Poor Survival in Epithelial Ovarian Cancer.
    Gynecol Oncol. 2015 Jun 23. pii: S0090-8258(15)30050.
    PubMed     Text format     Abstract available


  378. TAYLOR SE, Li R, Petschauer JS, Donovan H, et al
    Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
    Gynecol Oncol. 2015 Jun 23. pii: S0090-8258(15)30047.
    PubMed     Text format     Abstract available


  379. STRINGER-REASOR EM, Baker GM, Skor MN, Kocherginsky M, et al
    Glucocorticoid Receptor Activation Inhibits Chemotherapy-induced Cell Death in High-grade Serous Ovarian Carcinoma.
    Gynecol Oncol. 2015 Jun 23. pii: S0090-8258(15)30051.
    PubMed     Text format     Abstract available


  380. ERRIQUEZ J, Becco P, Olivero M, Ponzone R, et al
    TOP2A gene copy gain predicts response of epithelial ovarian cancers to liposomal pegylated doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
    Gynecol Oncol. 2015 Jun 19. pii: S0090-8258(15)30046.
    PubMed     Text format     Abstract available


  381. BURGER IA, Goldman DA, Vargas HA, Kattan MW, et al
    Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2015 Jun 17. pii: S0090-8258(15)30032.
    PubMed     Text format     Abstract available


  382. CASCALES P, Gil J, Feliciangeli E, Gil E, et al
    Hipec in ovarian cancer: Treatment of a new era or is it the end of the pipeline?
    Gynecol Oncol. 2015 Jun 16. pii: S0090-8258(15)30035.
    PubMed     Text format     Abstract available


  383. KARLSEN MA, Hogdall EV, Christensen IJ, Borgfeldt C, et al
    A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
    Gynecol Oncol. 2015 Jun 15. pii: S0090-8258(15)30041.
    PubMed     Text format     Abstract available


  384. SOPIK V, Rosen B, Giannakeas V, Narod SA, et al
    Why Have Ovarian Cancer Mortality Rates Declined? Part III. Prospects for the Future.
    Gynecol Oncol. 2015 Jun 15. pii: S0090-8258(15)30040.
    PubMed     Text format     Abstract available


  385. DECOLLOGNE S, Joshi S, Chung SA, Luk PP, et al
    Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells.
    Gynecol Oncol. 2015 Jun 13. pii: S0090-8258(15)30037.
    PubMed     Text format     Abstract available


  386. SOPIK V, Iqbal J, Rosen B, Narod SA, et al
    Why Have Ovarian Cancer Mortality Rates Declined? Part II. Case-fatality.
    Gynecol Oncol. 2015 Jun 13. pii: S0090-8258(15)30038.
    PubMed     Text format     Abstract available


  387. SOPIK V, Iqbal J, Rosen B, Narod SA, et al
    Why Have Ovarian Cancer Mortality Rates Declined? Part I. Incidence.
    Gynecol Oncol. 2015 Jun 13. pii: S0090-8258(15)30039.
    PubMed     Text format     Abstract available


  388. DOTTINO JA, Cliby WA, Myers ER, Bristow RE, et al
    Improving NCCN guideline-adherent care for ovarian cancer: value of an intervention.
    Gynecol Oncol. 2015 Jun 10. pii: S0090-8258(15)30034.
    PubMed     Text format     Abstract available


  389. DINKELSPIEL HE, Champer M, Hou J, Tergas A, et al
    Long-term mortality among women with epithelial ovarian cancer.
    Gynecol Oncol. 2015 Jun 5. pii: S0090-8258(15)30028.
    PubMed     Text format     Abstract available


  390. MITRA A, Davis DA, Tomar S, Roy L, et al
    In vivo tumor growth of high-grade serous ovarian cancer cell lines.
    Gynecol Oncol. 2015 Jun 4. pii: S0090-8258(15)30020.
    PubMed     Text format     Abstract available


  391. SCHRAUWEN S, Coenegrachts L, Cattaneo A, Hermans E, et al
    The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.
    Gynecol Oncol. 2015 Jun 4. pii: S0090-8258(15)30027.
    PubMed     Text format     Abstract available


  392. LAFARGUE CJ, Bristow RE
    Transdiaphragmatic Cardiophrenic Lymph Node Resection for Stage IV Ovarian Cancer.
    Gynecol Oncol. 2015 Jun 3. pii: S0090-8258(15)30025.
    PubMed     Text format     Abstract available


    May 2015
  393. TRAN AQ, Cohen JG, Li AJ
    Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
    Gynecol Oncol. 2015 May 30. pii: S0090-8258(15)30015.
    PubMed     Text format     Abstract available


  394. SUIDAN RS, Leitao MM Jr, Zivanovic O, Gardner GJ, et al
    Predictive value of the age-adjusted charlson comorbidity index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2015 May 30. pii: S0090-8258(15)30014.
    PubMed     Text format     Abstract available


  395. PREVIS R, Leath CA 3rd, Coleman RL, Herzog TJ, et al
    Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
    Gynecol Oncol. 2015 May 30. pii: S0090-8258(15)30017.
    PubMed     Text format     Abstract available


  396. PEEL AB, Barlow CE, Leonard D, DeFina LF, et al
    Cardiorespiratory Fitness in Survivors of Cervical, Endometrial, and Ovarian Cancer: The Cooper Center Longitudinal Study.
    Gynecol Oncol. 2015 May 27. pii: S0090-8258(15)30009.
    PubMed     Text format     Abstract available


  397. SMALETZ O, Diz MD, do Carmo CC, Sabbaga J, et al
    A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
    Gynecol Oncol. 2015 May 27. pii: S0090-8258(15)30005.
    PubMed     Text format     Abstract available


  398. BOONE JD, Dobbin ZC, Michael Straughn J, Buchsbaum DJ, et al
    Ovarian and cervical cancer patient derived xenografts: the past, present, and future.
    Gynecol Oncol. 2015 May 27. pii: S0090-8258(15)30004.
    PubMed     Text format     Abstract available


  399. SCALICI J, Finan MA, Black J, Harmon MD, et al
    Minority participation in Gynecologic Oncology Group (GOG) Studies.
    Gynecol Oncol. 2015 May 22. pii: S0090-8258(15)00932.
    PubMed     Text format     Abstract available


  400. TOZZI R, Giannice R, Cianci S, Tardino S, et al
    Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.
    Gynecol Oncol. 2015 May 21. pii: S0090-8258(15)00915.
    PubMed     Text format     Abstract available


  401. GUTH U, Arndt V, Stadlmann S, Huang DJ, et al
    Epidemiology in ovarian carcinoma: lessons from autopsy.
    Gynecol Oncol. 2015 May 21. pii: S0090-8258(15)00921.
    PubMed     Text format     Abstract available


  402. KOLOMEYEVSKAYA N, Eng KH, Khan AN, Grzankowski KS, et al
    Cytokine Profiling of Ascites at Primary Surgery Identifies an Interaction of Tumor Necrosis Factor-alpha and Interleukin-6 in Predicting Reduced Progression-Free Survival in Epithelial Ovarian Cancer.
    Gynecol Oncol. 2015 May 19. pii: S0090-8258(15)00914.
    PubMed     Text format     Abstract available


  403. RABAN O, Peled Y, Krissi H, Goldberg N, et al
    The Significance of Paracardiac Lymph-Node Enlargement In Patients With Newly Diagnosed Stage IIIC Ovarian Cancer.
    Gynecol Oncol. 2015 May 19. pii: S0090-8258(15)00912.
    PubMed     Text format     Abstract available


  404. BROWN AJ, Sun CC, Urbauer DL, Bodurka DC, et al
    Feeling Powerless: Locus of Control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients.
    Gynecol Oncol. 2015 May 16. pii: S0090-8258(15)00874.
    PubMed     Text format     Abstract available


  405. PATANKAR S, Burke WM, Hou JY, Tergas AI, et al
    Risk stratification and outcomes of women undergoing surgery for ovarian cancer.
    Gynecol Oncol. 2015 May 11. pii: S0090-8258(15)00866.
    PubMed     Text format     Abstract available


  406. ESCAYOLA, Ferron G, Romeo M, Torrent JJ, et al
    The impact of pleural disease on the management of advanced ovarian cancer.
    Gynecol Oncol. 2015 May 9. pii: S0090-8258(15)00872.
    PubMed     Text format     Abstract available


  407. DITTO A, Martinelli F, Bogani G, Lorusso D, et al
    Long-term Safety of Fertility Sparing Surgery in Early Stage Ovarian Cancer: Comparison to Standard Radical Surgical Procedures.
    Gynecol Oncol. 2015 May 9. pii: S0090-8258(15)00873.
    PubMed     Text format     Abstract available


  408. SEAGLE BL, Yang CP, Eng KH, Dandapani M, et al
    TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
    Gynecol Oncol. 2015 May 6. pii: S0090-8258(15)00868.
    PubMed     Text format     Abstract available


    April 2015
  409. SCHRAUWEN S, Depreeuw J, Coenegrachts L, Hermans E, et al
    Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Gynecol Oncol. 2015 Apr 28. pii: S0090-8258(15)00857.
    PubMed     Text format     Abstract available


  410. MIYASAKA A, Oda K, Ikeda Y, Sone K, et al
    PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-alpha/VEGF pathway in endometrial cancer.
    Gynecol Oncol. 2015 Apr 22. pii: S0090-8258(15)00835.
    PubMed     Text format     Abstract available


  411. HIRTE H, Lheureux S, Fleming GF, Sugimoto A, et al
    A Phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A Trial of the Princess Margaret, Chicago and California Phase II Consortia.
    Gynecol Oncol. 2015 Apr 17. pii: S0090-8258(15)00828.
    PubMed     Text format     Abstract available


  412. TOUHAMI O, Trinh XB, Gregoire J, Sebastianelli A, et al
    Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer.
    Gynecol Oncol. 2015 Apr 17. pii: S0090-8258(15)00827.
    PubMed     Text format     Abstract available


  413. SUH DH, Park JY, Lee JY, Kim BG, et al
    The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study.
    Gynecol Oncol. 2015 Apr 11. pii: S0090-8258(15)00789.
    PubMed     Text format     Abstract available


  414. LIAO JB, Yip YY, Swisher EM, Agnew K, et al
    Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.
    Gynecol Oncol. 2015 Apr 9. pii: S0090-8258(15)00772.
    PubMed     Text format     Abstract available


  415. EDQVIST PH, Huvila J, Forsstrom B, Talve L, et al
    Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
    Gynecol Oncol. 2015 Apr 7. pii: S0090-8258(15)00783.
    PubMed     Text format     Abstract available


  416. PARK JY, Kim DY, Suh DS, Kim JH, et al
    Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
    Gynecol Oncol. 2015 Apr 1. pii: S0090-8258(15)00782.
    PubMed     Text format     Abstract available


    March 2015
  417. COLEMAN RL, Sill MW, Bell-McGuinn K, Aghajanian C, et al
    A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An N
    Gynecol Oncol. 2015 Mar 24. pii: S0090-8258(15)00759.
    PubMed     Text format     Abstract available


  418. ROQUE DM, Ratner ES, Silasi DA, Azodi M, et al
    Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Gynecol Oncol. 2015 Mar 17. pii: S0090-8258(15)00683.
    PubMed     Text format     Abstract available


  419. GEELS YP, van der Putten LJ, van Tilborg AA, Lurkin I, et al
    Immunohistochemical and genetic profile of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Gynecol Oncol. 2015 Mar 12. pii: S0090-8258(15)00682.
    PubMed     Text format     Abstract available


  420. MEISEL JL, Hyman DM, Jotwani A, Zhou Q, et al
    The role of systemic chemotherapy in the management of granulosa cell tumors.
    Gynecol Oncol. 2015;136:505-11.
    PubMed     Text format     Abstract available


    February 2015
  421. MARCHIO C, De Filippo MR, Ng CK, Piscuoglio S, et al
    PIKing the type and pattern of PI3K pathway mutations in endometrial endometrioid carcinomas.
    Gynecol Oncol. 2015 Feb 18. pii: S0090-8258(15)00650.
    PubMed     Text format     Abstract available


  422. LU SM, Chang-Halpenny C, Hwang-Graziano J
    Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.
    Gynecol Oncol. 2015 Feb 7. pii: S0090-8258(15)00589.
    PubMed     Text format     Abstract available


    January 2015
  423. MEYER LA, Nick AM, Shi Q, Wang XS, et al
    Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients.
    Gynecol Oncol. 2015 Jan 31. pii: S0090-8258(15)00590.
    PubMed     Text format     Abstract available


  424. SORENSEN RD, Schnack TH, Karlsen MA, Hogdall CK, et al
    Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities - A systematic review.
    Gynecol Oncol. 2015 Jan 20. pii: S0090-8258(15)00538.
    PubMed     Text format     Abstract available


  425. GROWDON WB, Groeneweg J, Byron V, DiGloria C, et al
    HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
    Gynecol Oncol. 2015 Jan 17. pii: S0090-8258(15)00537.
    PubMed     Text format     Abstract available


  426. HEFLER-FRISCHMUTH K, Lafleur J, Hefler L, Polterauer S, et al
    Plasma fibrinogen levels in patients with benign and malignant ovarian tumors.
    Gynecol Oncol. 2015 Jan 7. pii: S0090-8258(15)00003.
    PubMed     Text format     Abstract available


    December 2014
  427. MIZUNO T, Suzuki N, Makino H, Furui T, et al
    Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.
    Gynecol Oncol. 2014 Dec 23. pii: S0090-8258(14)01560.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: